Bad Blood Secrets and Lies in a Silicon Valley Startup
1-
- Taschenbuch ausgewählt
- eBook
-
Sprache:Englisch
-
Verlag:Random House LLC US
9,99 €
inkl. gesetzl. MwSt.,
- Kostenlose Lieferung ab 30 € Einkaufswert
- Versandkostenfrei für Bonuscard-Kund*innen
Beschreibung
Produktdetails
Einband
Taschenbuch
Erscheinungsdatum
01.02.2020
Verlag
Random House LLC USSeitenzahl
400
Maße (L/B/H)
20,3/13,2/2,4 cm
Gewicht
344 g
Sprache
Englisch
ISBN
978-0-525-43199-2
NATIONAL BESTSELLER • The gripping story of Elizabeth Holmes and Theranos—one of the biggest corporate frauds in history—a tale of ambition and hubris set amid the bold promises of Silicon Valley, rigorously reported by the prize-winning journalist. With a new Afterword covering her trial and sentencing, bringing the story to a close.
“Chilling ... Reads like a thriller ... Carreyrou tells [the Theranos story] virtually to perfection.” —The New York Times Book Review
In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the next Steve Jobs: a brilliant Stanford dropout whose startup “unicorn” promised to revolutionize the medical industry with its breakthrough device, which performed the whole range of laboratory tests from a single drop of blood. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes’s worth at an estimated $4.5 billion. There was just one problem: The technology didn’t work. Erroneous results put patients in danger, leading to misdiagnoses and unnecessary treatments. All the while, Holmes and her partner, Sunny Balwani, worked to silence anyone who voiced misgivings—from journalists to their own employees.
“Chilling ... Reads like a thriller ... Carreyrou tells [the Theranos story] virtually to perfection.” —The New York Times Book Review
In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the next Steve Jobs: a brilliant Stanford dropout whose startup “unicorn” promised to revolutionize the medical industry with its breakthrough device, which performed the whole range of laboratory tests from a single drop of blood. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes’s worth at an estimated $4.5 billion. There was just one problem: The technology didn’t work. Erroneous results put patients in danger, leading to misdiagnoses and unnecessary treatments. All the while, Holmes and her partner, Sunny Balwani, worked to silence anyone who voiced misgivings—from journalists to their own employees.
Kundinnen und Kunden meinen
Sehr empfehlenswert
A. Bernhard am 25.10.2021
Bewertungsnummer: 1594136
Bewertet: Buch (Taschenbuch)
Dieses Buch ist eines der spannendsten Sachbücher, das ich seit langem gelesen habe. Die Geschichte rund um Theranos ist packend und schockierend zugleich und auch der Aufbau des Buches hat mich überzeugt. Ich habe es sehr zügig gelesen und kann es nur empfehlen.
Kurze Frage zu unserer Seite
Vielen Dank für Ihr Feedback
Wir nutzen Ihr Feedback, um unsere Produktseiten zu verbessern. Bitte haben Sie Verständnis, dass wir Ihnen keine Rückmeldung geben können. Falls Sie Kontakt mit uns aufnehmen möchten, können Sie sich aber gerne an unseren Kund*innenservice wenden.
zum Kundenservice